Introducing SAHPRA’s Online Directory for OTC Medicines

By Staff Writer

October 19, 2023

SAHPRA Online OTC Medicines Directory

The South African Health Products Regulatory Authority (SAHPRA) has announced a new online directory of over-the-counter (OTC) drugs. Optimised for mobile use, this directory includes all registered over-the-counter medicines in Schedule 0, 1, and 2. It serves as an essential guide for the general public and medical professionals.

Enhancing One’s Capability to Access Crucial Information

The team first introduced the online directory on January 6th, 2021, with a planned launch in May 2021. The directory aims to provide detailed information from the Patient Information Leaflet (PIL) for all registered over-the-counter products. These products include commercially available complementary medicines in South Africa, but only after their registration. If a PIL isn’t available yet, the directory will use the Professional Information (PI) instead. 

Together with the Self-Care Association of South Africa, SAHPRA have worked to compile this directory. The system will provide a secure login to every over-the-counter medicine manufacturer. The Responsible Pharmacist or any designated company representative can use this login. They will have the ability to input all relevant approved PILs for their OTC items. If a PIL isn’t available, they can enter the PI. The system will already have the names of these items loaded.

Streamlining Access to Essential Information

Users are able to swiftly and easily locate the information they require thanks to the extensive search feature provided by the SAHPRA OTC online directory. It will be possible to conduct searches in the SAHPRA OTC online directory by making reference to:

  • therapeutic category or pharmacological categorisation,
  • product name; or
  • active ingredient, such as paracetamol and aspirin.

The platform is not meant to be utilised for marketing-related activities. The only logo or branding that will be allowed is that of the SAHPRA, hence no other logos or brands will be allowed.

The introduction of this online database is a significant step toward achieving greater transparency, accountability, and accessibility in the field of healthcare.

Reference url

Recent Posts

National Health Insurance South Africa
    

Reassuring the Private Sector on National Health Insurance South Africa: A Path to Universal Coverage

🌍 How can South Africa achieve universal healthcare without sidelining private providers?

The National Health Insurance (NHI) represents a pivotal shift in South Africa’s commitment to offering equitable health coverage. Recent assurances from the Treasury highlight a desire to collaborate with the private sector, aiming for a hybrid approach that leverages the best of both worlds.

Curious about how this initiative could reshape the healthcare landscape? Jump into the full article for in-depth insights on the challenges, potential funding models, and the international lessons that can guide this transformative journey.

#SyenzaNews #HealthEconomics #HealthTech #HealthcarePolicy

MASLD CKD socioeconomic link
    

Exploring the MASLD CKD Socioeconomic Link

🌍 Are socioeconomic factors influencing your health more than you realise?

Our latest article looks into the intriguing link between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD), revealing significant geographical and socioeconomic correlations. Discover how understanding these relationships can inform public health strategies and improve health equity worldwide.

Dive into the findings and implications for health outcomes!

#SyenzaNews #HealthEconomics #globalhealth #HealthcareInnovation

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.